A pathologist explains why your GLP-1 stopped working (it didn't)

Dr. Amin Hedayat says the flat scale at month 8 or month 14 looks like failure, but the trials show it's the shape the drug is supposed to make.

I'm a Pathologist. Do This When Ozempic & Mounjaro "Stop Working."

Maria is four months into tirzepatide, the drug in Mounjaro and Zepbound. She lost 11% of her body weight faster than she thought possible. For six weeks the number hasn't moved.

James is 11 months in, top dose of semaglutide, the drug in Ozempic and Wegovy. He's down 16%. For three months, nothing.

Denise is 14 months in, except her insurance stopped covering it four months ago. Nine pounds came back already and she's trying to figure out how many more will follow.

All three are typing the same sentence into the same forum: I think it stopped working. What should I do now?

1. The graph that shows what a plateau actually is

In the big semaglutide trial, 1,961 adults were assigned to the drug or placebo for 68 weeks. The drug line drops fast for six months, then slows, then flattens around week 60. Average loss: 14.9%. Placebo: 2.4%.

The tirzepatide trial with 2,539 adults shows the same shape, flattening toward week 72 at about 21% at the highest dose.

The longest trial is the four-year heart study of semaglutide with 17,600 people. Weight came down for the first 65 weeks, then stayed flat at about 10% below baseline for as long as four years while people kept taking the drug.

Look at what those three lines have in common. Fast, then slower, then flat. A flat scale doesn't mean the drug stopped. It means the effect met the counterpressure of a smaller, adapting body.

A flat scale doesn't automatically mean the drug stopped.Dr. Amin Hedayat, MD

Why this matters if you haven’t started yet: Every line is an average. In the tirzepatide trial at top dose, 57% of people lost 20% or more. That means 43% didn't. Some lost 35%, some lost 8%. The comparison that matters is you against your own line, not your friend's.

2. The bucket: why every plateau happens

Picture a bucket with a small hole in the bottom and a hose filling it from the top. The water level is your weight. The hose is what you eat. The hole is what your body burns.

When the bucket is full, the pressure at the bottom is high and it drains fast. A bigger body burns more just to exist. Turn the hose down, that's the drug lowering appetite, and the level starts dropping. As the level drops, the pressure drops and the hole drains slower. A smaller body burns less.

The level keeps falling until the slower drain matches the smaller hose. Then it holds.

Kevin Hall at the NIH published a model of this in 2024. Weight loss itself triggers the body to push back, mostly by driving appetite up. These drugs weaken that push-back. That's why the line keeps falling far longer on these drugs than on diet alone, where the push-back usually wins within months.

A plateau doesn't prove the drug failed. Most often, it means the drug's effect has finally met the counterpressure of a smaller, adapting body.

3. Your metabolism after weight loss

In 1995, researchers at Rockefeller University published a study in the New England Journal of Medicine. They had people lose 10 to 20% of their body weight under controlled conditions, then measured how much energy their bodies burned at the new weight.

The bodies burned less than a body that size should. Roughly 6 to 8 calories a day less for every kilogram of lean tissue, which works out to a few hundred calories a day. This is called adaptive thermogenesis. The body doesn't just get smaller, it gets more thrifty.

In 2016, the NIH followed 14 contestants from The Biggest Loser six years after the show. Their resting metabolism was still about 700 calories a day below where it started, and about 500 of that couldn't be explained by their size.

If you've plateaued and you're eating less than a person your size should be able to eat, the pattern you're seeing is not unusual. It doesn't mean your metabolism is broken. It means the bucket drains a little slower.

4. Maria's plateau: dose and tolerability

Maria's line went flat at 5 milligrams of tirzepatide because the nausea at the next step was rough and her prescriber said let's hold here.

The trial shows what that means. At 5 milligrams, average loss was about 15%. At 10 milligrams, about 19.5%. At 15, about 21%. Same drug, deeper level at the higher dose.

Maria's question isn't why did tirzepatide stop working. It's have I reached the effect of the dose I can tolerate, and what are the appropriate options from here. That's a prescriber conversation about dose and side effects.

5. James's plateau: is there a different drug

James's line went flat at 2.4 milligrams of semaglutide, the top dose. The trial average was 14.9%, and he's past it at 16%. He can't go deeper on that drug.

In 2025, the first head-to-head trial came out. 751 adults with obesity, no diabetes, assigned to the highest dose they could handle of either tirzepatide or semaglutide for 72 weeks. Tirzepatide: 20.2%. Semaglutide: 13.7%.

The trial was paid for by Lilly, who makes tirzepatide, and it was open-label, meaning everyone knew which drug they were on. Still the best head-to-head evidence we have.

James doesn't need to conclude he failed semaglutide. He needs to ask whether his current drug is still the best drug for his situation.

6. Denise's plateau: weight regain after the drug stops

Denise isn't at a plateau. She's on the other side of one, and her situation has two trials.

In the STEP 4 trial, 803 people took semaglutide for 20 weeks and lost about 10.6%. Then two thirds stayed on the drug and one third were switched to placebo. Over the next 48 weeks, the drug group kept losing another 7.9%. The placebo group regained 6.9%.

In the extension of the first semaglutide trial, when the drug and the coaching both stopped, people regained about two thirds of what they'd lost within a year.

That doesn't mean everyone regains the same amount. Obesity behaves like a chronic disease, and when you remove the treatment, the biology it was holding back comes forward.

Denise's question is different from the other two: is there a path back to a drug, and until there is, what can she hold?

7. What the weight you lose is made of

When you lose a lot of weight, some of it is muscle. In March 2026, researchers pooled 20 randomized trials, nearly 16,000 people, and measured what fraction of the weight lost was lean tissue.

On these drugs, between 25% and 39%, depending on the drug. With diet and exercise alone, about 26%, so the drugs aren't uniquely eating muscle.

When the lifestyle program included resistance training, the lean-tissue fraction dropped to 17.5%. Same weight loss, but more of it fat loss instead of muscle loss.

Arriving at a lower weight with your strength intact is a different outcome from arriving there weaker. Protein at the level your physician sets, resistance training twice a week, enough total food to do both, and a conversation with your prescriber if the appetite suppression is so strong you can't meet those needs.

Why this matters if you haven’t started yet: This is what all three of them share. Muscle is the part of the deal you have some say over.

What to do this week: four questions for your prescriber

Stop treating the weight you measure daily as a verdict. Weighing yourself regularly is fine, but a plateau is a trend over weeks, not a number on a random Tuesday.

Write down your dose and the actual reason you're on that dose. Bring your prescriber four questions.

Is this a dose-and-tolerability issue? Is this the expected response to this drug? Is a different treatment medically appropriate for me at this time? Or have I reached a weight that now needs to be maintained rather than pushed lower?

Count your protein intake for five days, because most people have no idea where they are.

The scale can stop while the drug is still working. That's what the trials show, for years. The line flattens where the drug's effect meets a smaller, adapting body, and that body burns a little less than its size predicts.

There are three kinds of plateau: dose, drug, and life after the drug. Each one is a different conversation. The number on the scale doesn't tell you whether the drug failed, and it doesn't tell you whether you failed. Your graph tells you more, and it's a prescriber question. Sometimes the most important thing a plateau tells you is that the next phase has begun.

Questions people ask

Why did my GLP-1 stop working after a few months?

A flat scale doesn't automatically mean the drug stopped. In the big trials, weight drops fast for six months, then slows and flattens around week 60 to 72 while people stay on the drug. The plateau is the shape the drug is supposed to make, not a sign of failure.

Does Mounjaro work better than Ozempic if I've plateaued?

In the first head-to-head trial, 751 adults lost an average of 20.2% on tirzepatide versus 13.7% on semaglutide at 72 weeks. If you've plateaued at the top dose of semaglutide, switching to tirzepatide is a conversation worth having with your prescriber.

How much weight will I regain after stopping a GLP-1?

In the STEP 4 trial, people who switched from semaglutide to placebo regained 6.9% over 48 weeks. In another trial extension, people regained about two thirds of what they'd lost within a year. The amount varies, but the direction is consistent when the drug stops.

DA
Dr. Amin Hedayat, MD

Dr. Amin Hedayat is a pathologist trained in obesity medicine and metabolic health who teaches the evidence behind GLP-1 medications. 491,899 views on the original video.

Watch the original on YouTube →

Trending Topics